促红细胞生成素及其衍生物的心脏保护作用被引量：1

下载PDF

导出

摘要促红细胞生成素(EPO)能直接促进红细胞生成,可用于预防和治疗多种原因引起的贫血。EPO广泛分布于人体各个系统,除促造血作用外,还具有抗炎、抗凋亡、促进新生血管生成等多种作用,并可通过这些作用发挥广泛的组织保护效能。然而,长期大剂量应用EPO必然增加高血压、血栓形成等风险。氨甲酰化促红细胞生成素(carbamylated erythropoietin,CEPO)作为EPO衍生物的代表,不仅药代动力学特征与EPO相似,且可通过抗炎、抗凋亡、促进新生血管生成等多种作用减轻心、脑、肾等器官的缺血-再灌注损伤,但其无促红细胞生成活性,不会增加高血压及血栓形成风险。因此,CEPO的应用前景比EPO更为广阔。该文将EPO及CEPO的心脏保护作用作一综述。

作者张丽陈新星王志禄

机构地区兰州大学第一临床医学院陕西省博爱医院神经内科

出处《国际心血管病杂志》 2011年第2期92-94,共3页 International Journal of Cardiovascular Disease

关键词促红细胞生成素氨甲酰促红细胞生成素心脏保护

分类号 R541 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献28

1Wang Y, Zhang ZG, Rhodes K, et al. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia[J]. Br J Pharmacol, 2007,151 (8) : 1377 -1384.
2Imamura R, Okumi M, Iska Y,et al. Carbamylated erythropoietin improves angiogenesis and protects the kidneys from ischemia reperfusion injury [[J].Cell Transplant, 2008, 17(1-2) : 135-141.
3Moon C, Krawczyk M, Paik D,et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties [J]. J Pharmacol Exp Ther, 2006,316(3) :999-1005.
4FiordalisoF, Crnenti S, StaszewskyL,et. A nonerythropoietic derivative of erythropoietin protects the myocardium from isehemia-reperfusion injury[J]. Proc Natl Acad Sei U S A, 2005,102(6):2046-2051.
5Siren AL, Knerlich F, Poser W, et al. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain[J]. Acta Neuropathol, 2001,101 (3) : 271-276.
6Lipsic E, Schoemaker RG, van der Meer P,et al. Protective effects of erythropoietin in cardiac ischemia~ from bench to bedside[J]. J Am Coil Cardiol, 2006,48(11);2161-2167.
7Tramontano AF, Muniyappa R, Black AD, et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway[J]. Biochem Biophys Res Commun, 2003,308 (4) : 990-994.
8Moon C, Krawezyk M, Ahn D,et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats[J]. Proc Natl Acad Sci U S A, 2003,100(20):11612-11617.
9Hirata A, Minamino T, Asanuma H,et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts[J]. Cardiovasc Drugs Ther, 2005, 19(1) :33-40.
10Namiuchi S, Kagaya Y, Ohta J, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention[J]. J Am Coll Cardiol, 2005,45(9) : 1406-1412.

二级参考文献18

1Caiola K,Cheng JW.Use of erythropoietin in heart failure management[J].Ann Pharmacother,2004,38(12):2145-2149.
2Silverberg DS,Wexler D,Shep SD,et al.The effect of connection of mild anemia in severe,resistant congestive heart failure using subcutaneous Erythropoietin and intravenous iron:a randomized controlled study[J].J Am Coll Cardiol,2001,37(7):1775-1780.
3van derMeer P,Voors AA,Lipsie E,et al.Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure[J].J Am coll Cardiol,2004,44(1):63-67.
4Engler RL, Dahlgren MD, Peterson MA, et al. Accumulation of polymorphonuclear leukocytes during 3-h experimental myocardial ischemia. Am J Physiol, 1986,251 (1 Pt 2) :H93-100.
5Valleio JG, Knuefermann P, Mann DL, et al. Group B Streptococcus induces TNF-alpha gene expression and activation of the transcription factors NF-kappa B and activator protein-1 in human cord blood monocytes. J Immunol,2000,165:419-425.
6Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nature Medicine, 1997,3 : 894- 899.
7Fan H, Sun B, Gu Q, et al. Oxygen radicals trigger activation of NF-kappaB and AP-1 and upregulation of ICAM-1 in reperfused canine heart. Am J Physiol Heart Circ Physiol,2002,282 :H1778- 1786.
8Maulik N, Sasaki H, Addya S, et al. Regulation of cardiomyocyte apoptosis by redox-sensitive transcription factors. FEBS Lett, 2000,485:7-12.
9Valen G. Signal transduction through nuclear factor kappa B in ischemia- reperfusion and heart failure. Basic Res Cardiol, 2004, 99:1-7.
10Sack MN, Smith RM, Opie LH. Tumor necrosis factor in myocardial hypertrophy and ischaemia: ananti-apoptotic perspective. Cardiovasc Res, 2000,45:688-695.